Full Thickness Macular Hole; Should it be Handled Subacutely?

Full Thickness Macular Hole Clinical Trial

Official title:

Full Thickness Macular Hole; Should it be Handled Subacutely?

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05828251
• Other study ID #: Rigshospitalet-RS studie
• Status: Recruiting
• Phase: N/A
• Start date: April 30, 2023
• Est. completion date: April 1, 2028

Study information

• Verified date: April 2024
• Source: Rigshospitalet, Denmark
• Contact: Asrin Rasul, MD
• Phone: 004522365420
• Email: asrin.rasul[@]regionh.dk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Full thickness macular hole, FTMH, is a retinal disease involving the fovea that cause central vision loss, metamorphopsia and central scotoma. The most effective treatment for FTMH is a pars plana vitrectomy and a tamponade with expansile gas. It is well known that vitrectomy accelerates cataract development. Vitrectomy can therefore be combined with cataract surgery in the same setting, a procedure that is shown to be safe, although increased inflammation and rates of central macular edema have been reported in some studies. Cataract surgery can also be performed prior or deferred until compromising the visual acuity after vitrectomy. Cataract-surgeries are more challenging in vitrectomized eyes due to lack of vitreous support and risk of loose zonules. The normal practice for FTMH at our department is therefore cataract surgery followed by vitrectomy 4 weeks later. A combined phaco-vitrectomy procedure is offered to patients who are at the labor market or when general anesthesia is required for the surgery. In non-presbyopic patients (<50 years) only vitrectomy is performed. The visual improvement after surgery seems to be dependent on preoperative characteristics, such as the preoperative visual acuity, size of the hole and the duration of symptoms. The duration of symptoms is a known prognostic factor, and recently shown that the longer duration, the worse visual outcome. The precise timeframe for the optimal final outcome is not known. The combined surgery is known to be safe in the treatment for epiretinal membrane, where a intravitreal gasfill is not necessary. However, the use of gas in FTHM surgery causes risk of increased movement of the newly inserted intraocular lens. This can lead to increased anterior segment inflammation with ensuing vision threatening cystic macular edema, as mentioned above. The purpose of this study is to investigate whether small FTMH with a short duration of symptoms have better visual outcome with a prompt combined phako-vitrectomy (within two weeks), compared to the current standard of care of receiving cataract surgery as soon as possible and vitrectomy 4 weeks later. How the delay of surgery affects the visual outcome will also be investigated, by including patients with longer duration of symptoms. The main hypothesis is that the chance of better visual outcome is higher for macular holes with early surgery compared to the current standard of care and that the duration of symptoms has significant impact on the visual outcome. Method The study consists of 2 parts. 1. Patients with idiopathic FTMH <400µm in diameter (as defined by The international vitreomacular traction study group classification), with a duration of symptoms of less than 30 days will be randomized into 2 groups: Group1: Combined phaco-vitrectomy within 2 weeks (after referral). Group 2: Current standard of care with cataract surgery as soon as possible and vitrectomy 4 weeks later. 2. Group 3: Patients with small holes <400µm, with a duration of symptoms of more than 3 months and less than one year will be included in this part of the study. These patients will be treated and followed as in Group 2. They will be reviewed a total of 7 times in Group 1 and 9 times in Group 2 and 3: a preoperative examination followed by 6/8 postoperative examinations. Additional examinations will be scheduled if needed.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 56
• Est. completion date: April 1, 2028
• Est. primary completion date: April 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Idiopathic full thickness macular hole
• Duration of symptoms of <30 days for Group 1 and 2
• Duration of symptoms of 3-12 months for Group 3
• FTMH size <400µm
• >18 years
• Able to give informed consent
• Compliance for postoperative positioning

Exclusion Criteria:

• High myopia (=-3)
• Traumatic macular hole
• Prior ocular surgery, including cataract surgery
• Other ocular diseases compromising the visual acuity (i.e., AMD, diabetic retinopathy, previous vein occlusion)
• Posterior vitreous detachment (Weiss ring)

Related Conditions & MeSH terms

• Full Thickness Macular Hole
• Retinal Perforations

Intervention

Procedure:
• Vitrectomy (Sequential phakoemulsification and vitrectomy)
Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.
• Combined phako-vitrectomy
Phakoemulsication and pars plana vitrectomy are performed in the same setting. This procedure is normally only offeres to selected cases at our department.
• Phako (Sequential phakoemulsification and vitrectomy)
Standard treatment for FTMH at our department with phakoemulsification followed by pars plana vitrectomy and gas 4 weeks later.

Locations

Country	Name	City	State
Denmark	Rigshospitalet, Denmark	Glostrup	Copenhagen

Sponsors (1)

Lead Sponsor	Collaborator
Rigshospitalet, Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Visual acuity	Best corrected visual acuity measured with ETDRS, the ETDRS scoe will be converted to LogMAR	12 months after vitrectomy
Secondary	Metamorphopsia	Measured by M-charts, for vertical and horisontal metamorfopisa. The M-charts consist of 19 dotted (dot size is 0.1°) lines with dot intervals ranging from 0.2° to 2.0° of visual angle.	12 months after vitrectomy
Secondary	Hole closure rates	Either the hole closes og it doesn't.	Measured 4 weeks after surgery
Secondary	Microperimetry	Microperimetry is a procedure to assess retinal sensitivity while fundus is directly examined; it enables exact correlation between macular pathology and corresponding functional abnormality. Measured in mean retinal sensitivity (dB)	12 months after surgery
Secondary	Anterior chamber inflammation	(FM). The FM is based on the measurement principle of laser light scattering detection. The instrument uses a diode laser beam to scan a measuring window that is projected inside the anterior chamber of the eye. As an aqueous protein (component of inflammation) passes through the focal point of the laser,light scattering occurs. The intensity of the scattered light (directly proportional to the amount of protein particles-flare) is detected by a photo-multiplier tube (PMT), which generates an electrical signal. This signal is immediately digitized to eliminate outside noise interference and are processed by a computer which displays the results for user analysis. The unit of measurement employed by the FM is "Photon Count" per millisecond.	1 day and 1 week after the first surgery